Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 • 5,383 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

2007 • 3,700 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

2004 • 1,709 citations

Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer

2003 • 1,248 citations

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

2002 • 910 citations

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

1999 • 840 citations

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 • 828 citations

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

2003 • 642 citations

Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors

2004 • 605 citations

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

2002 • 583 citations

FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets

2003 • 541 citations

Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.

1995 • 317 citations

EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma

1998 • 243 citations

A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

1999 • 201 citations

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

2006 • 175 citations

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling

2005 • 164 citations

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

2005 • 160 citations

Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]

2005 • 137 citations

Treatment of Ménétrier's Disease with a Monoclonal Antibody against the Epidermal Growth Factor Receptor

2000 • 118 citations

Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations.

1992 • 105 citations

The epidermal growth factor receptor as a target for colorectal cancer therapy

2005 • 90 citations

Prostaglandin E2 Synergistically Enhances Receptor Tyrosine Kinase-dependent Signaling System in Colon Cancer Cells

2004 • 86 citations

A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

2005 • 63 citations

Uncommon Presentations of Hodgkin's Disease

2003 • 60 citations

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

2003 • 57 citations

Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells

2005 • 39 citations